Voxtalisib (XL765) | pan-PI3K Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	934493-76-2
Formula :	C₁₃H₁₄N₆O
M.W :	270.29
SMILES Code :	CCN1C2=NC(N)=NC(C)=C2C=C(C3=NNC=C3)C1=O
Synonyms :	XL765; SAR245409
MDL No. :	MFCD20276656
InChI Key :	RGHYDLZMTYDBDT-UHFFFAOYSA-N
Pubchem ID :	16123056

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302
Precautionary Statements:	P280-P305+P351+P338

U87IDHmut cells	12 μM	24 hours	To evaluate the effect of XL765 on U87IDHmut cell proliferation, showing a 61.0 ± 10.6% reduction in cell number.	PMC6642106
MDA-MB-231	IC50 75.2 µM	24 hours	Investigate the effect of XL765 on circRNA and linRNA expression, showing upregulation of circRNA and downregulation of linRNA	PMC10204552
MCF-7	IC50 91.4 µM	24 hours	Investigate the effect of XL765 on circRNA and linRNA expression, showing upregulation of circRNA and downregulation of linRNA	PMC10204552
Chronic lymphocytic leukemia cells	0.86 µM (IC50)	48 hours	Therapeutic effect on chronic lymphocytic leukemia through apoptotic caspase-dependent mechanisms and effectively inhibits T-cell-mediated cytokine production	PMC9237521
SUM149 and MDA-MB-231	0.5 µM	6 hours	To assess the effect of combination treatment on TNBC cell migration and invasion capabilities	PMC4643087
NHAIDHmut cells	32 μM	72 hours	To evaluate the effect of XL765 on NHAIDHmut cell proliferation, showing a 55.7 ± 16% reduction in cell number.	PMC6642106
GBM 39	5.0 μM	72 hours	Evaluate the cytotoxicity of XL765 on GBM 39 cells, showing a concentration-dependent decrease in cell viability	PMC3064692
GBM GS-2	7.7 μM	72 hours	Evaluate the cytotoxicity of XL765 on GBM GS-2 cells, showing a concentration-dependent decrease in cell viability	PMC3064692
GBM 12	3.7 μM	72 hours	Evaluate the cytotoxicity of XL765 on GBM 12 cells, showing a concentration-dependent decrease in cell viability	PMC3064692
GBM 8	5.7 μM	72 hours	Evaluate the cytotoxicity of XL765 on GBM 8 cells, showing a concentration-dependent decrease in cell viability	PMC3064692
SUM149 TNBC cells	0.005-20 μM	72 hours	Evaluate the synergistic effect of Voxtalisib with birinapant, results showed no significant synergistic effect observed in SUM149 cells	PMC8747014
MDA-MB-231	40 nM	72 hours	To evaluate the synergistic inhibitory effect of PI3K inhibitor SAR245409 combined with MEK inhibitor AS703026 on TNBC cell proliferation	PMC4643087
ST88	0.25-20 μM	96 hours	XL765 significantly inhibited MPNST cell growth with an IC50 of 2.49 μM	PMC3416967
MPNST642	0.25-20 μM	96 hours	XL765 significantly inhibited MPNST cell growth with an IC50 of 1.93 μM	PMC3416967
STS26T	0.25-20 μM	96 hours	XL765 significantly inhibited MPNST cell growth with an IC50 of 1.75 μM	PMC3416967
MPNST724	0.25-20 μM	96 hours	XL765 significantly inhibited MPNST cell growth with an IC50 of 0.86 μM	PMC3416967
S462	0.25-20 μM	96 hours	XL765 significantly inhibited MPNST cell growth with an IC50 of 0.81 μM	PMC3416967

Nude mice	U87IDHmut intracranial tumor model	Oral	30 mg/kg	Twice daily, continuous treatment	To evaluate the effect of XL765 on U87IDHmut intracranial tumor model, showing that XL765 treatment significantly prolonged animal survival.	PMC6642106
Mice	Gastrointestinal stromal tumor (GIST) model	Oral gavage	30 mg/kg (6-hour treatment), 20 mg/kg (7-day treatment)	Single dose for 6-hour treatment or twice daily for 7-day treatment	To evaluate the effect of Voxtalisib on GIST tumor proliferation. Results showed that 6-hour treatment inhibited PI3K signaling (pAKT, pS6, and p4EBP1) but increased MAPK phosphorylation. Seven days of treatment reduced tumor cell proliferation by 70%.	PMC5635919
SCID mice	MPNST724 and STS26T xenograft models	Oral	30 mg/kg/bid	Twice daily, continuous treatment	XL765 significantly inhibited local and metastatic growth of MPNST xenografts	PMC3416967
Nude mice	GS-2 and U87-MG GBM orthotopic models	Oral	30mg/kg voxtalisib twice daily	Twice daily, continuous treatment	To monitor the effect of voxtalisib alone or in combination with TMZ, finding a significantly lower lactate-to-pyruvate ratio post-treatment, associated with enhanced survival	PMC4873419
Mice	Aldh5a1−/− mouse model	Intraperitoneal injection	5 mg/kg/day and 10 mg/kg/day	Once daily until death	To evaluate the effects of mTOR inhibitors on lifespan and body weight in aldh5a1?/? mice. Results showed that Tor2, XL-765, and tat-Bec1 significantly extended lifespan and improved body weight.	PMC5114712
Nude mice	Intracranial xenograft GBM 39 model	Oral gavage	50 mg/kg	Twice daily, 6 hours apart, for 2 weeks	Evaluate the inhibitory effect of XL765 on GBM 39 tumor growth in vivo, showing a 13-fold reduction in median tumor bioluminescence and improvement in median survival compared to control	PMC3064692

{[proInfo.proName]}

CAS No.: 934493-76-2

{[proInfo.proName]}

CAS No.: 934493-76-2

Alternative Products

Product Details of Voxtalisib

Safety of Voxtalisib

Related Pathways of Voxtalisib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT01410513	Indolent Non-Hodgkin Lymphoma\|... More >>Mantle Cell Lymphoma\|Chronic Lymphocytic Leukemia Less <<	PHASE1	COMPLETED	2025-05-14	Investigational Site Number 84... More >>0004, Aurora, Colorado, 80045, United States\|Investigational Site Number 840006, Augusta, Georgia, 30912, United States\|Investigational Site Number 840002, Charleston, South Carolina, 29406, United States Less <<
NCT01403636	Lymphoma	PHASE2	COMPLETED	2025-09-14	Investigational Site Number 84... More >>0012, Los Angeles, California, 90033, United States\|Investigational Site Number 840104, Fort Meyers, Florida, 33919, United States\|Investigational Site Number 840006, Augusta, Georgia, 30912, United States\|Investigational Site Number 840011, Maywood, Illinois, 60153, United States\|Investigational Site Number 840010, Kansas City, Kansas, 66160-7321, United States\|Investigational Site Number 840013, Lexington, Kentucky, 40536, United States\|Investigational Site Number 840007, Paducah, Kentucky, 42002, United States\|Investigational Site Number 840004, Boston, Massachusetts, 02115, United States\|Investigational Site Number 840015, St Louis, Missouri, 63110, United States\|Investigational Site Number 840014, Canton, Ohio, 44718, United States\|Investigational Site Number 840001, Philadelphia, Pennsylvania, 19111, United States\|Investigational Site Number 840002, Morgantown, West Virginia, 26506, United States\|Investigational Site Number 036002, Clayton, 3168, Australia\|Investigational Site Number 036001, Hobart, 7001, Australia\|Investigational Site Number 036005, Kingswood, 2747, Australia\|Investigational Site Number 036003, Perth, 6000, Australia\|Investigational Site Number 056003, Bruxelles, 1000, Belgium\|Investigational Site Number 056002, Gent, 9000, Belgium\|Investigational Site Number 056001, Leuven, 3000, Belgium\|Investigational Site Number 250002, Montpellier, 34295, France\|Investigational Site Number 250001, Pierre Benite Cedex, 69495, France\|Investigational Site Number 250004, Rennes, 35033, France\|Investigational Site Number 250005, Rouen Cedex, 76038, France\|Investigational Site Number 250003, Villejuif Cedex, 94805, France\|Investigational Site Number 276003, Frankfurt Am Main, 60590, Germany\|Investigational Site Number 276002, Jena, 07747, Germany\|Investigational Site Number 276001, Ulm, 89081, Germany\|Investigational Site Number 528001, Amsterdam, 1105 AZ, Netherlands\|Investigational Site Number 528003, Groningen, 9713 GZ, Netherlands\|Investigational Site Number 528002, Rotterdam, 3075 EA, Netherlands Less <<
NCT01596270	Neoplasm Malignant	PHASE1	COMPLETED	2025-10-14	Investigational Site Number 84... More >>0001, Detroit, Michigan, 48201, United States\|Investigational Site Number 840002, New Brunswick, New Jersey, 08903, United States\|Investigational Site Number 840003, Dallas, Texas, 75230, United States Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.70mL 0.74mL 0.37mL	18.50mL 3.70mL 1.85mL	37.00mL 7.40mL 3.70mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed